Cart 0

MarketsandMarkets

Rat Model Market -Global Forecast to 2021

$5,650.00

Report Published By: MarketsandMarkets
Publication Date : Jan-17
No. Of Pages: 256

The rat model market is projected to reach USD 588.9 million by 2021 from USD 387.7 million in 2016, growing at a CAGR of 8.7% during the forecast period.

Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth. However, increased benefits of cryopreservation and regulations & laws formulated for ethical use of animals in research are restraining the growth of the market to a certain extent.

The global rat model market is segmented on the basis of model type, service, technology, therapeutic area, end user, care product, and region. In 2016, North America is expected to account for the largest share of the global rat model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate during the forecast period. Factors such as less stringent regulations on the use of animal models for research in the region, international alliances for R&D activities in China, growth in regenerative medicine, biomedical, and medical research in Japan, growing presence of global players, development of bioclusters to boost biotechnology industry in India, ongoing biomedical research activities in Australia, and rising pharmaceutical and biotechnology R&D activities are likely to propel the market in the Asia-Pacific region.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (expansions; new product launches; collaborations/agreement/partnerships/alliance, funding; licensing, contract, acquisitions, and expansions) to increase their market shares and establish a strong foothold in the global market.

In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the rat model market place.
? By Company Type: Tier 1: 50%, Tier 2: 42%, Tier 3: 8%
? By Designation: Director Level: 58%, C-level: 25%, Others: 17%
? By Region: North America: 46%, Europe: 31%, APAC: 15%, RoW: 8%
The prominent players in the global rat model market include Charles River Laboratories International, Inc. (U.S.), Envigo (U.K.), and Taconic Biosciences, Inc. (U.S.). Other players include Laboratory Corporation of America Holdings (U.S.), Janvier Labs (France), Transviragen, Inc. (U.S.), genOway SA (France), Biomere (U.S.), Transposagen Biopharmaceuticals, Inc. (U.S.), and Horizon Discovery Group plc (U.K.).

Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the products and services offered by top players in the rat model market. The report analyzes the rat model market by model type, service, technology, therapeutic area, end user, care product, and region
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the rat model market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for rat model across various regions
• Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the rat model market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the rat model market

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 RESEARCH METHODOLOGY 24
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 25
2.2.1 SECONDARY RESEARCH 25
2.2.1.1 Key data from secondary sources 25
2.2.2 PRIMARY RESEARCH 27
2.2.2.1 Key data from primary sources 28
2.2.2.2 Key Insights from primary sources 29
2.2.2.3 Key industry insights 29
2.3 MARKET SIZE ESTIMATION METHODOLOGY 30
2.4 MARKET FORECAST METHODOLOGY 32
2.5 MARKET DATA VALIDATION AND TRIANGULATION 33
2.6 ASSUMPTIONS FOR THE STUDY 34
3 EXECUTIVE SUMMARY 35
3.1 INTRODUCTION 35
3.2 CONCLUSION 42
4 PREMIUM INSIGHTS 43
4.1 RAT MODEL MARKET OVERVIEW 43
4.2 REGIONAL ANALYSIS: GLOBAL RAT CARE PRODUCT MARKET, BY TYPE 44
4.3 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA, 2016 & 2021 45
4.4 REGIONAL SNAPSHOT OF THE GLOBAL RAT MODEL MARKET 45
?
5 MARKET OVERVIEW 46
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 48
5.2.1 DRIVERS 48
5.2.1.1 Advancements in gene editing tools set to augment the demand for rat models 48
5.2.1.2 Advantages offered by rats over mice 49
5.2.1.3 Continuous support in the form of investments and grants 50
5.2.1.4 Increased demand for personalized humanized rat models due to growing consumption of personalized medicines 51
5.2.1.5 Increase in R&D activities carried out by pharmaceutical and biotechnology companies 52
5.2.2 RESTRAINTS 52
5.2.2.1 Regulations & laws formulated for ethical use of animals 52
5.2.2.1.1 The Animal Welfare Act (AWA) 53
5.2.2.1.2 Public health service policy (PHS) on humane care and use of laboratory animals 53
5.2.2.2 Increased benefits offered by cryopreservation 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Increased production of monoclonal antibodies 53
5.2.3.2 Rising demand of humanized rat models 54
5.2.4 CHALLENGES 54
5.2.4.1 Advancements in zebrafish model development 54
5.2.4.2 Development of methods alternative to animal testing 55
6 CLINICAL TRIALS & RESEARCH STUDIES ASSESSMENT 56
6.1 INTRODUCTION 57
6.2 CLINICAL TRIALS 57
6.3 RESEARCH STUDIES 60
7 GLOBAL RAT MODEL MARKET, BY MODEL TYPE 65
7.1 INTRODUCTION 66
7.2 OUTBRED RATS 68
7.3 INBRED RATS 69
7.4 KNOCKOUT/GENETICALLY ENGINEERED RATS 70
7.5 HYBRID/CONGENIC RATS 71
7.6 CONDITIONED/SURGICALLY MODIFIED RATS 72
7.7 IMMUNODEFICIENT RATS 73
?
8 GLOBAL RAT MODEL MARKET, BY SERVICE 74
8.1 INTRODUCTION 75
8.2 BREEDING 77
8.3 CRYOPRESERVATION 78
8.4 QUARANTINE 79
8.5 REDERIVATION 80
8.6 MODEL IN-LICENSING 81
8.7 GENETIC TESTING 82
8.8 OTHERS 83
8.8.1 SURGICAL SERVICES 83
8.8.2 LINE RESCUE SERVICES 83
8.8.3 IN VIVO PHARMACOLOGY SERVICES 83
9 GLOBAL RAT MODEL MARKET, BY TECHNOLOGY 85
9.1 INTRODUCTION 86
9.2 CRISPR 88
9.3 MICROINJECTION 89
9.4 EMBRYONIC STEM CELL INJECTION 90
9.5 NUCLEAR TRANSFER 91
9.6 OTHER TECHNOLOGIES 92
10 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA 94
10.1 INTRODUCTION 95
10.2 TOXICOLOGY 96
10.3 ONCOLOGY 98
10.3.1 NEW PRODUCT LAUNCHES FOR ONCOLOGY RESEARCH 98
10.3.2 CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES 99
10.4 IMMUNOLOGY AND INFLAMMATION 100
10.5 NEUROLOGY 101
10.6 DIABETES 103
10.7 OTHERS 104
11 GLOBAL RAT MODEL MARKET, BY END USER 106
11.1 INTRODUCTION 107
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 108
11.3 ACADEMIC & RESEARCH INSTITUTIONS 109
11.4 CONTRACT RESEARCH ORGANIZATIONS (CRO) 111
?
12 GLOBAL RAT MODEL MARKET, BY CARE PRODUCT 112
12.1 INTRODUCTION 113
12.2 CAGES 115
12.3 FEED 116
12.4 BEDDING 117
12.5 OTHER CARE PRODUCTS 118
13 GLOBAL RAT MODEL MARKET, BY REGION 119
13.1 INTRODUCTION 120
13.2 NORTH AMERICA 122
13.2.1 U.S. 127
13.2.1.1 Growing biomedical research in the U.S. 127
13.2.1.2 Preclinical activities by CROs and pharmaceutical R&D 128
13.2.1.3 Continued and responsible use of animals ensured by animal care organizations 129
13.2.1.4 Development of biosimilars product boosting the demand for preclinical services 130
13.2.1.5 Monoclonal antibody production to augment the use of rat models 131
13.2.1.6 Partnership between CROs and pharmaceutical companies 131
13.2.2 CANADA 134
13.2.2.1 Growing stem cell research activities in Canada 134
13.2.2.2 Government support for development of protein drugs is expected to drive the rat model market 135
13.3 EUROPE 138
13.3.1 GERMANY 143
13.3.1.1 Launch of Pro-Test Deutschland 143
13.3.1.2 Flourishing biotechnology industry 143
13.3.2 U.K. 147
13.3.2.1 Investors demand strong statistics for animal studies in the U.K. 147
13.3.2.2 Increase in cell therapy preclinical research 147
13.3.3 FRANCE 150
13.3.3.1 Funding for Rare Disease Projects in France 150
13.3.4 RUSSIA 153
13.3.4.1 Growing biomedical industry in Russia 153
13.3.5 REST OF EUROPE 157
13.3.5.1 Growth in biotech and pharma sector of Italy 157
13.3.5.2 Growing investments in research by Sweden & Denmark 157
13.3.5.3 Focus on rare disease research projects 157
13.3.5.4 Growth in Biosimilars market to lead to increased preclinical activities 158
?
13.4 ASIA-PACIFIC 161
13.4.1 CHINA 166
13.4.1.1 International alliances for R&D activities in China 166
13.4.1.2 Initiatives to reduce longer approval times 167
13.4.1.3 Intellectual property (IP) breaches, a challenge for the China market 167
13.4.1.4 Mandatory animal testing for all pharmaceutical drugs and cosmetics in China 168
13.4.1.5 Increasing investments from government and private sectors in China’s life sciences sector 168
13.4.2 JAPAN 172
13.4.2.1 Growth in biomedical and medical research in Japan 172
13.4.2.2 Research in regenerative medicine 172
13.4.2.3 Focus on cancer research and treatment 173
13.4.3 INDIA 176
13.4.3.1 Growth of the pharmaceutical industry in India 176
13.4.3.2 Development of bio-clusters to boost India’s biotechnology 176
13.4.3.3 Growing presence of global players 177
13.4.3.4 Shift of outsourcing preclinical activities from India to European nations 177
13.4.3.5 Weak intellectual property environment in India 178
13.4.3.6 Limited infrastructural facilities in India, a major hindrance for growth of the rat model market 178
13.4.4 REST OF ASIA-PACIFIC 181
13.4.4.1 Ongoing Biomedical research activities in Australia to strengthen the market 181
13.4.4.2 Growth in translational and biomedical research in Singapore 182
13.4.4.3 Increase in animal research in Malaysia 183
13.4.4.4 Government support for strong academic and commercial R&D activities in Taiwan 184
13.4.4.5 Rising pharmaceutical and biotechnology R&D activities in Korea 184
13.5 REST OF THE WORLD 187
13.5.1.1 Pharmaceutical, biotechnology, and research industries in Brazil to drive market growth 188
13.5.1.2 Favorable business environment for pharmaceutical and biotechnology industries in Saudi Arabia and the UAE 189
13.5.1.3 Increasing investments in Mexico 190
14 COMPETITIVE LANDSCAPE 194
14.1 OVERVIEW 194
14.2 MARKET SHARE ANALYSIS 195
14.2.1 INTRODUCTION 195
14.2.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (U.S.) 196
14.2.3 ENVIGO (U.K.) 196
14.2.4 TACONIC BIOSCIENCES, INC. (U.S.) 197
?
14.3 COMPETITIVE SITUATION AND TRENDS 197
14.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 198
14.5 ACQUISITIONS 200
14.6 EXPANSIONS 202
14.7 NEW PRODUCT LAUNCHES 204
14.8 OTHER STRATEGIES 205
15 COMPANY PROFILES 206
(Overview, Products and Services, Financials, Strategy & Development)*
15.1 INTRODUCTION 206
15.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 207
15.3 TACONIC BIOSCIENCES, INC. 213
15.4 ENVIGO 217
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 220
15.6 JANVIER LABS 223
15.7 GENOWAY S.A. 225
15.8 BIOMERE 227
15.9 TRANSPOSAGEN BIOPHARMACEUTICALS, INC. 229
15.10 HORIZON DISCOVERY GROUP PLC 230
15.11 TRANSVIRAGEN, INC. 236
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
16 APPENDIX 237
16.1 DISCUSSION GUIDE 237
16.2 OTHER DEVELOPMENTS 242
16.2.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 242
16.2.2 TACONIC BIOSCIENCES, INC. 243
16.2.3 ENVIGO 244
16.2.4 LABORATORY CORPORATION OF AMERICA HOLDINGS 245
16.2.5 GENOWAY S.A. 245
16.2.6 HORIZON DISCOVERY GROUP PLC 246
16.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 248
16.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 250
16.5 AVAILABLE CUSTOMIZATIONS 251
16.6 RELATED REPORTS 252
16.7 AUTHOR DETAILS 253

* indicates required information

* indicates required information


Share this Product


More from this collection